Examine Pay-to-Play Scheme Involving Super PAC Donations & Medicare Policy

As your constituent, I urge you to investigate the apparent corrupt pay-to-play arrangement between Extremity Care's multi-million-dar super PAC donations and the Trump administration's delay of Medicare reimbursement restrictions that would have adversely affected the company's profits. The facts are striking and troubling. Extremity Care donated $5 million to MAGA Inc. in February 2024, immediately securing its owner direct access to President Trump at a Mar-a-Lago dinner in March. There, he presented a flier opposing Medicare coverage limits on the company's skin substitute products. Within weeks, the Trump administration delayed implementing the Biden-era policy that would have restricted reimbursement for these expensive bandages. The timing and sequence sure look like a textlbook pay-to-play arrangement. This is not mere political access—it directly benefited Extremity Care's bottom line. The company's skin substitutes command extraordinary prices, with some products listed at nearly $12,000 per square inch. Medicare spending on these products exploded from $256 million in 2021 to $10 billion in 2024, with significant portions flowing to Extremity Care. The Biden administration proposed limiting coverage to 17 products backed by rigorous research—a list that excluded Extremity Care's bandages. The Trump administration's delay protected billions in revenue streams for the company. This arrangement raises serious questions about whether government healthcare decisions are being driven by political donations rather than public health or fiscal responsibility. Taxpayers are footing the bill for inflated prices while Medicare's resources are diverted to companies that donate generously to presidential super PACs. Congress must act decisively: Launch a formal investigation into communications between Trump administration officials and Extremity Care representatives following the $5 million donation. Subpoena all records documenting the decision to delay the Medicare reimbursement policy, including discussions with company lobbyists. Examine the broader pattern of super PAC donations from healthcare companies followed by favorable regulatory treatment. Implement safeguards preventing campaign donations from influencing Medicare coverage and reimbursement decisions. The integrity of Medicare depends on decisions made in patients' interests, not corporate donors' interests. I urge you to hold the administration accountable.